Psychedelic-assisted therapy, particularly using compounds like psilocybin, presents a promising new treatment avenue for individuals with treatment-resistant mental illnesses, driven by significant research advancements, although legal and social stigmas pose challenges to its mainstream acceptance and accessibility. #MentalHealth #PsychedelicTherapy #DepressionTreatment #UK #US
The article discusses the potential approval of psilocybin, the active ingredient in magic mushrooms, as a treatment for treatment-resistant depression (TRD) by the FDA, following successful results from Compass Pathways' clinical trials demonstrating significant symptom improvement in participants, highlighting the possibility of a new era in psychedelic medicine. #PsychedelicMedicine #MentalHealth #DepressionTreatment #USA
Connectoma, a neurotechnology company backed by mental health leaders like Marian Rojas Estapé, has launched its first center in Madrid in partnership with Veram clinic, offering a personalized transcranial magnetic stimulation treatment for depression that reportedly achieves up to 79% remission in difficult-to-treat patients, and aims to expand access to this innovative therapy across Spain. #Neurotechnology #MentalHealth #DepressionTreatment #ES #US
